Shares of Metsera Inc. (MTSR) have gained 6.8% over the past four weeks to close the last trading session at $35.32, but ...

MetseraMTSR got a positive adjustment to its Relative Strength (RS) Rating, from 88 to 93.Please watch the video at Investors ...

Metsera is also joining its metabolic medicines peers who are developing oral GLP-1 drugs. The biotech’s candidate is MET-224o, an ultra-long acting GLP-1 receptor agonist made with technology ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today anno Metsera Secures $215 Million Series B ...

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

Metsera, Inc., a clinical-stage biopharmaceutical company focused on treating obesity and metabolic diseases, announced its first quarter 2025 financial results, highlighting significant progress ...

Investment Overview - Metsera Latest To Join Obesity Market Challengers. Obesity is forecast by some analysts to become a >$200bn market, with up to 16 new drugs on the market by 2031. Eli Lilly ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for ...

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by early 2030s Jan 10 ...

Metsera said its drug’s half-life of 19 days supports once-monthly dosing. That would be an advantage over the once-weekly dosing of the GLP-1 drugs currently available and the clinical-stage ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of ...